PMID-17018654 – CJC-1295 Pulsatile GH Secretion in Humans
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
Quick Reference
| Property | Value |
|---|---|
| PMID | 17018654 |
| DOI | 10.1210/jc.2006-1702 |
| Year | 2006 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Study Type | Human clinical study |
| Evidence Level | II |
| Sample | Healthy adult human volunteers |
| Peptide(s) Studied | CJC-1295 NO DAC |
Key Findings
- CJC-1295 maintains the physiological pulsatile pattern of GH secretion in humans even during continuous stimulation
- This is a critical safety finding — tonic (non-pulsatile) GH elevation is associated with adverse metabolic effects and potential tumor risk
- Trough GH levels were enhanced, indicating improved basal GH tone without abolishing natural pulsatility
- IGF-1 levels were significantly increased, confirming downstream GH axis activation
- The pulsatile pattern was preserved across the duration of study observation
- Demonstrates that CJC-1295 works synergistically with endogenous somatostatin tone to maintain physiological GH dynamics
Study Design
Healthy adult volunteers received CJC-1295 administration. Frequent blood sampling (every 10-20 minutes) over extended periods was used to characterize the GH secretory pattern using deconvolution analysis. GH pulse frequency, amplitude, trough levels, and total GH secretion were quantified. IGF-1 levels were measured at baseline and during treatment. Comparisons were made to pre-treatment baseline GH profiles in the same subjects.
Limitations
- Relatively small sample of healthy volunteers — may not reflect GH dynamics in GH-deficient or elderly populations
- Short study duration — long-term pulsatility maintenance not confirmed
- Used the DAC-conjugated version; clinical extrapolation to "no DAC" variant requires caution
- No body composition or clinical outcome endpoints measured
- No placebo control group explicitly described
Clinical Relevance
This is one of the most important human studies for CJC-1295 and a cornerstone reference for clinicians prescribing GH secretagogue protocols. The preservation of pulsatile GH secretion addresses the primary safety concern with GH-releasing agents: the risk of tonic GH elevation mimicking acromegaly. This finding supports the clinical use of CJC-1295 (particularly the "no DAC" variant in combination with ipamorelin) as a physiological approach to GH optimization, distinct from exogenous GH injection which produces non-pulsatile pharmacokinetics.
Related
#research #observational #CJC-1295 #evidence-level-II